Proactive Investors - Run By Investors For Investors

Milestone Scientific says hospital in Italy becomes first in country to use its epidural system

The device’s numerical, graphical and auditory verification gives anesthesia provides added confidence, according to Milestone
A medical facility
Numerical verification gives anesthesia providers added confidence, Milestone says

Milestone Scientific Inc (NYSEAMERICAN: MLSS) announced Monday that a hospital in Italy has become the first in the country to use the company’s CompuFlo system for epidurals in labor and delivery.

The medical-device company said in a statement that the CompuFlo systems helps customers, including Ospedale Pugliese Ciaccio di Catanzaro in Italy’s Calabria region, reduce failure rates and accidental punctures.

READ: Nemaura says improved continuous glucose monitor halves time needed for reliable reading

The device’s numerical, graphical and auditory verification gives anesthesia provides added confidence, according to Livingston, New Jersey-based Milestone.

CompuFlo is 99% successful in identifying the epidural space even for patients with a higher body-mass index, according to the company, citing a study in Anesthesia & Analgesia Journal.

“Pugliese Ciaccio’s new standard of care with the CompuFlo epidural instrument is good for both providers and patients,” said Pino Purrone of PF Medical, a CompuFlo distributor in the Calabria region. “We anticipate more hospitals will follow suit.”

Shares of Milestone traded at $0.35 in Monday’s New York trading.

Contact Dennis Fitzgerald at [email protected]

View full MLSS profile View Profile

Milestone Scientific Inc Timeline

Related Articles

cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Scientist at work
May 28 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use